Principal investigators and research institutions seeking to buy CJC-1295 No DAC require verified, analytical-grade material to ensure assay reproducibility. PX1 Research supplies USA-manufactured CJC-1295 No DAC subjected to rigorous RP-HPLC purity testing and mass spectrometry confirmation for advanced preclinical research.
Principal investigators and research institutions seeking to buy CJC-1295 No DAC require verified, analytical-grade material to ensure assay reproducibility. PX1 Research supplies USA-manufactured CJC-1295 No DAC subjected to rigorous RP-HPLC purity testing and mass spectrometry confirmation for advanced preclinical research.
Qualified investigators seeking to buy CJC-1295 No DAC for laboratory experimentation can procure high-purity, USA-manufactured peptide material directly through PX1 Research. Every lot undergoes rigorous RP-HPLC and mass spectrometry verification in an ISO 17025 accredited facility, ensuring >98% sequence purity and low endotoxin levels for reliable in vitro and preclinical models.
When procuring raw peptide reagents for cell culture or animal assays, sourcing integrity is paramount. Inconsistent purity or undetected trifluoroacetate (TFA) salt remnants can alter cellular responses, compromise somatotroph receptor binding assays, and invalidate experimental datasets. PX1 Research mitigates these experimental variables by manufacturing all lyophilized peptides in GMP-compliant domestic facilities, accompanying each batch with a comprehensive, lot-traceable Certificate of Analysis (COA).
To streamline procurement for academic and institutional entities, orders ship same-day from primary logistics hubs in California and Arizona. Researchers can order standard experimental quantities of CJC-1295 No DAC online or set up a dedicated wholesale institutional account for high-volume screening protocols.
CJC-1295 No DAC is a synthetic, 29-amino acid peptide derivative representing a tetrasubstituted analog of human Growth Hormone-Releasing Hormone (GHRH 1-29). In academic literature, this compound is frequently referred to as Modified GRF 1-29 (Mod GRF 1-29). The chemical structure features strategic amino acid substitutions at positions 2, 8, 15, and 27 relative to native GHRH, specifically D-Ala2, Gln8, Ala15, and Leu27.
These structural modifications were engineered to overcome the rapid enzymatic cleavage characteristic of native GHRH (1-29) amide, which is degraded within minutes by dipeptidyl peptidase IV (DPP-IV) in serum. By substituting native L-alanine at position 2 with D-alanine, the peptide exhibits enhanced steric hindrance against DPP-IV cleavage, extending its biological plasma half-life from approximately 5–12 minutes to roughly 30 minutes in preclinical animal models.
Crucially, CJC-1295 No DAC lacks the Drug Affinity Complex (DAC) maleimide-propionic acid linker. While the DAC modification enables irreversible covalent binding to serum albumin for week-long retention, the 'No DAC' format preserves a physiological, short-acting pharmacokinetic curve. This allows researchers to simulate natural, pulsatile somatotrope signaling in controlled experimental environments without causing prolonged, continuous receptor occupancy.
As a functional GHRH analog, CJC-1295 No DAC binds with high affinity to the Growth Hormone-Releasing Hormone Receptor (GHRHR), a Class B1 G-protein coupled receptor expressed predominantly on the plasma membrane of anterior pituitary somatotrophs. Binding initiates a conformational change that activates the intracellular Gs alpha subunit, stimulating transmembrane adenylyl cyclase activity.
Adenylyl cyclase activation converts intracellular adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). Rising cAMP concentrations activate protein kinase A (PKA), leading to the phosphorylation of cAMP response element-binding protein (CREB) and the influx of extracellular calcium through L-type voltage-gated calcium channels. This intracellular cascade prompts the exocytosis of pre-stored Growth Hormone (GH) vesicles into circulation.
In cell culture and animal models, this signal transduction pathway leads to a transient, physiological pulse of endogenous growth hormone secretion. Elevated systemic GH subsequently interacts with hepatic GH receptors, upregulating gene transcription and raising circulating levels of insulin-like growth factor 1 (IGF-1). The preservation of this episodic axis makes CJC-1295 No DAC a primary reference standard in endocrinological research targeting somatotropic axis regulation.
Preclinical investigation into CJC-1295 No DAC centers primarily on its capacity to sustain elevated GH and downstream IGF-1 expression without blunting natural feedback loops. In rodent models of musculoskeletal injury, sustained elevation of the GH/IGF-1 axis has been shown to accelerate satellite cell activation, enhance localized collagen deposition, and promote protein synthesis in damaged myofibers.
Research in connective tissue models indicates that GHRH agonist administration supports fibroblast proliferation and extracellular matrix remodeling. In vitro assays using dermal and tendinous tissue explants suggest that downstream IGF-1 induction upregulates lysyl oxidase transcription, an enzyme necessary for the covalent cross-linking of structural collagen strands during tissue repair.
Additionally, preclinical studies evaluating systemic metabolic parameters indicate that pulsatile GH release stimulated by CJC-1295 No DAC promotes lipid oxidation and nitrogen retention in catabolic animal states. Researchers investigating age-related somatopause utilize this compound to analyze whether restoring youthful GH amplitude can attenuate cellular senescence and vascular endothelial dysfunction in preclinical disease models. Detailed mechanism breakdowns are indexed across the PX1 Research Library.
When designing comparative secretagogue protocols, investigators often evaluate CJC-1295 No DAC against other GHRH analogs and growth hormone secretagogue receptor (GHSR-1a) agonists. Understanding the distinct receptor kinetics, plasma half-lives, and physiological mechanisms of these compounds allows researchers to select the precise reagent for their specific experimental objectives.
Unlike CJC-1295 with DAC, which forms a permanent adduct with circulating albumin to elevate GH levels continuously for 6–8 days, CJC-1295 No DAC displays a sharp peak and rapid clearance profile (half-life ~30 minutes). This short duration mimics physiological pulsatility, avoiding the potential downregulation of pituitary GHRH receptors observed during uninterrupted activation.
When compared to alternative GHRH analogs such as Tesamorelin or Sermorelin, CJC-1295 No DAC demonstrates greater resistance to enzymatic cleavage due to its tetrasubstituted design, yielding higher receptor activation per molar dose. In multi-receptor assays, researchers frequently co-administer CJC-1295 No DAC alongside selective ghrelin receptor agonists like Ipamorelin to investigate synergistic dual-pathway GH release, wherein simultaneous GHRHR and GHSR-1a stimulation produces a amplified release response without altering serum cortisol or prolactin.
To preserve structural integrity and prevent peptide aggregation during in vitro or preclinical preparation, strict sterile reconstitution standards must be maintained. CJC-1295 No DAC is supplied as a lyophilized white powder sealed under vacuum in borosilicate glass vials.
Prior to reconstitution, allow the vial to equilibrate to room temperature to prevent atmospheric moisture condensation upon unsealing. Using a sterile syringe, inject an appropriate volume of standard laboratory diluent, such as sterile Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Normal Saline (0.9% NaCl), directing the fluid stream against the glass wall rather than directly onto the lyophilized cake.
Gently swirl the vial in a circular motion until the solute fully dissolves into a clear, colorless solution. Never shake or agitate the vial vigorously, as mechanical shear stress can induce peptide denaturation and hydrophobic aggregation. For cell culture experiments sensitive to benzyl alcohol, sterile phosphate-buffered saline (PBS, pH 7.4) may be utilized, provided the solution is used immediately or micro-aliquoted and stored at low temperatures.
Lyophilized CJC-1295 No DAC remains stable at -20°C for up to 24 months from the date of manufacture when protected from light and ambient moisture. For long-term archiving in institutional chemical repositories, storage at -80°C is recommended to minimize baseline degradation over multi-year research projects.
Once reconstituted in bacteriostatic water, the liquid solution should be refrigerated at 2°C to 8°C and used within 28 days. Unpreserved aqueous solutions (such as those reconstituted in plain sterile water or PBS) exhibit degraded chemical stability and must be used within 24 hours to prevent microbial contamination and peptide hydrolysis.
Avoid repeated freeze-thaw cycles of reconstituted liquid solutions. Freeze-thaw dynamics generate ice crystal boundaries that physically shear the peptide backbone, resulting in loss of biological potency. Investigators should prepare single-use sub-aliquots in sterile, low-protein-binding polypropylene tubes prior to initial freezing if long-term liquid storage is required.
Rigorous quality control differentiates academic-grade reagents from substandard commercial products. Every lot of CJC-1295 No DAC manufactured for PX1 Research undergoes dual-tier analytical validation performed by independent ISO 17025 accredited testing facilities.
Purity is quantified via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). The resulting chromatogram must demonstrate a singular sharp peak corresponding to the intact 29-amino acid sequence, with overall chromatographic purity exceeding 98.0%. Minor secondary peaks representing truncated fragments or deamidation products are strictly limited to less than 2.0% cumulative area.
Sequence identity is confirmed using Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF), matching the observed molecular weight against the theoretical mass of 3367.97 Da. Furthermore, bacterial endotoxin testing is conducted via the Limulus Amebocyte Lysate (LAL) assay to ensure levels remain well below standard cell culture safety thresholds (<0.01 EU/μg), protecting sensitive in vitro models from inflammatory artifacts.
PX1 Research maintains a robust domestic supply chain designed to support individual academic laboratories, corporate biotechnology firms, and contract research organizations (CROs). All inventory is stored in climate-controlled facilities and dispatched in cold-pack insulated packaging when climate conditions demand protection.
Orders placed before 3:00 PM EST Monday through Friday ship same-day from distribution centers in California and Arizona, minimizing transit times and reducing transit-induced degradation. Detailed lot documentation, including batch-specific COAs, safety data sheets (SDS), and analytical spectra, is accessible directly via QR codes printed on product labeling.
For enterprise research requirements, custom synthesis options, bulk vial packaging, and scheduled batch supply contracts are available through the PX1 wholesale portal. All compounds are strictly designated for laboratory research use only.
What is CJC-1295 No DAC?
CJC-1295 No DAC (also known as Modified GRF 1-29) is a synthetic, tetrasubstituted 29-amino acid analog of human Growth Hormone-Releasing Hormone (GHRH). It is designed to resist enzymatic degradation by DPP-IV, providing a half-life of approximately 30 minutes in preclinical models while preserving natural, pulsatile somatotroph signaling.
How does CJC-1295 No DAC differ from CJC-1295 with DAC?
CJC-1295 No DAC lacks the Drug Affinity Complex (DAC) maleimide-propionic acid linker. Consequently, it does not bind covalently to serum albumin. This results in a short half-life (~30 minutes) and pulsatile GH release, whereas the DAC version exhibits an extended half-life (6–8 days) and produces continuous, non-pulsatile GH elevation.
What purity standards does PX1 Research require for CJC-1295 No DAC?
PX1 Research mandates that every batch of CJC-1295 No DAC achieves ≥98.0% purity as verified by RP-HPLC. Molecular weight and sequence identity are confirmed via ESI-MS or MALDI-TOF mass spectrometry, and endotoxin levels are verified below 0.01 EU/μg via LAL assay.
What diluent should be used to reconstitute CJC-1295 No DAC for in vitro laboratory assays?
For routine laboratory preparation, sterile Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Normal Saline (0.9% NaCl) is recommended. For cell culture experiments sensitive to preservatives, sterile phosphate-buffered saline (PBS, pH 7.4) may be used for immediate application.
How should lyophilized CJC-1295 No DAC be stored upon delivery?
Lyophilized CJC-1295 No DAC should be stored in a freezer at -20°C (or -80°C for long-term storage) protected from light and moisture. Under these conditions, the un-reconstituted peptide remains stable for up to 24 months.
Why is CJC-1295 No DAC studied alongside ghrelin receptor agonists like Ipamorelin?
In preclinical research, combining a GHRH receptor agonist (CJC-1295 No DAC) with a GHSR-1a ghrelin receptor agonist (Ipamorelin) activates two distinct intracellular pathways in somatotrophs, producing a synergistic, amplified release of growth hormone without elevating cortisol or prolactin.
What is the theoretical molecular weight of CJC-1295 No DAC?
The theoretical molecular weight of CJC-1295 No DAC (C152H252N44O42) is 3367.97 Da. Batch purity and identity are verified against this reference value using mass spectrometry prior to product release.
Can CJC-1295 No DAC be used in human clinical trials or personal applications?
No. CJC-1295 No DAC supplied by PX1 Research is strictly manufactured and labeled for laboratory research use only (RUO), including in vitro cellular assays and preclinical animal models. It is not for human or veterinary medical, therapeutic, or diagnostic use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.